紫杉醇联合奈达铂治疗晚期卵巢癌患者的临床研究

Clinical trial of paclitaxel combined with nedaplatin in the treatment of patients with advanced ovarian cancer

目的观察紫杉醇联合奈达铂腹腔灌注治疗晚期卵巢癌及对患者免疫功能的调节作用。方法将在我院接受治疗的晚期卵巢癌患者104例,按随机数字表法分为试验组和对照组,各52例。2组患者均于第1天给予紫杉醇135mg·m-2,第2天给予奈达铂100 mg·m-2,21 d为1个周期,连续化疗3个周期。对照组用静脉注射方式,试验组用腹腔灌注的方式。比较2组治疗后临床疗效及治疗前后血清肿瘤标志物水平、免疫功能变化,记录2组药物不良反应情况。结果治疗后,试验组和对照组总有效率分别为92. 31%,71. 15%,差异有统计学意义(P <0. 05)。治疗后,试验组和对照组患者血清CEA分别为(4. 48±1. 03)和(11. 83±2. 76) ng·mL-1,CA125分别为(8. 47±1. 82)和(14. 42±2. 57) U·mL-1,CA199分别为(13. 95±2. 82)和(28. 84±6. 43)U·mL-1,差异均有统计学意义(均P <0. 05)。治疗后,试验组CD3+、CD4+、CD8+比例及CD4+/CD8+与对照组相比,差异均有统计学意义(均P <0. 05)。试验组和对照组的药物不良反应发生率分别为23. 08%,46. 15%(P <0. 05)。结论紫杉醇联合奈达铂腹腔灌注化疗可明显降低晚期卵巢癌患者血清肿瘤标志物水平,有效调节机体免疫功能,安全有效。

Objective To investigate the regulating effect of paclitaxel combined with intraperitoneal perfusion using nedaplatin on immune function of patients with advanced ovarian cancer.Methods A total of 104 patients with advanced ovarian cancer treated in our hospital were divided into treatment group and control group according to the random number table method,52 cases in each group.Paclitaxel 135 mg·m-2 on first day and nedaplatin 100 mg·m-2 on second day were used for chemotherapy in both groups,21 d a course and patients were given 3 consecutive courses.Control group was given by intravenous injection and treatment group was given by intraperitoneal perfusion.The clinical efficacy,the levels of serum tumor markers,immune function changes before and after treatment were compared between the two groups,and the adverse drug reactions in two groups were recorded.Results After treatment,the total effective rates in treatment group and control group were 92.31%,71.15%,with significant difference(P<0.05).The serum CEA levels in treatment group and control group were(4.48±1.03)and(11.83±2.76)ng·mL-1,CA125 were(8.47±1.82)and(14.42±2.57)U·mL-1,CA199 were(13.95±2.82)and(28.84±6.43)U·mL-1,all with significant difference(all P<0.05).Compared with before treatment,the percentage of CD3+,CD4+CD8+and CD4+/CD8+in treatment group all had significant difference compared with control group(all P<0.05).The total incidence of adverse drug reactions in treatment group and control group were 23.08%,46.15%(P<0.05).Conclusion Paclitaxel combined with nedaplatin intraperitoneal infusion chemotherapy can significantly reduce the levels of serum tumor markers in patients with advanced ovarian cancer,effectively regulate the body’s immune function,which is safe and effective.